RESUMEN
Background: Excessive blood loss is a relevant complication of partial liver resection. Topical hemostatic agents have proven useful to improve the control of the bleeding in this among other surgical indications. Until now all of these products have been based on the action of thrombin. In contrast TT-173 is a new topical hemostatic agent based on recombinant tissue factor naturally incorporated into membrane vesicles. This work sought to assess the efficacy and toxicity of TT-173 in an animal model of liver resection.Materials and Methods: Procoagulant activity of 0.15, 0.41, and 1 mg of TT-173 was evaluated in pigs subjected the resection of hepatic lobe margins. The most effective of these doses was also compared against thrombin. In addition, the toxicity, local tolerance, systemic absorption, and immunogenicity of the product were investigated in rats subjected to liver biopsy lesion.Results: The three doses of TT-173 evaluated significantly reduced the bleeding time in liver lesions. The highest dose of product was significantly more effective than the others and thrombin. Application of high doses of TT-173 in rats did not cause any local or systemic alterations. Absorption into blood stream was negligible and no immunogenic reaction against the product was detected.Conclusions: TT-173 shows favorable pharmacodynamic properties for improving hemostasis in partial liver resection which support further investigation of the product in this surgical indication.
Asunto(s)
Pérdida de Sangre Quirúrgica/prevención & control , Hemostasis Quirúrgica/métodos , Hemostáticos/administración & dosificación , Hígado/lesiones , Tromboplastina/administración & dosificación , Administración Tópica , Animales , Modelos Animales de Enfermedad , Femenino , Hepatectomía/efectos adversos , Humanos , Hígado/irrigación sanguínea , Hígado/cirugía , Masculino , Ratas , Proteínas Recombinantes , PorcinosRESUMEN
The selective induction of tumor vascular thrombosis using truncated tissue factor (tTF) delivered via a target ligand is a promising novel antitumor strategy. In the present study, an antineuropilin1 (NRP1) monoclonal antibody (mAb)streptavidin (SA):tTFbiotin (B) composite system was established. In this system, antiNRP1mAb located tTF to the tumor vascular endothelial cell surface and induced vascular embolization. Due to their high binding affinity, SA and B were used to enhance thrombogenic activity. mAb was conjugated with SA using a coupling method with watersoluble 1ethyl3(3dimethylaminopropyl) carbodiimide and Nhydroxysulfosuccinimide. Biotinylated tTF (tTFB) was prepared using a Blabeling kit subsequent to the generation and purification of fusion protein tTF. Confocal microscopy and flow cytometry indicated that the antiNRP1mAbSA conjugate retained mAb targeting activity. The preservation of Bconjugate binding capacity was confirmed using a competitive ELISA, and factor Xactivation analysis revealed that tTFB retained the procoagulant activity exhibited by tTF. Live imaging was performed to assess mAbSA distribution and tumortargeting capability, and this yielded promising results. The results of in vivo studies in mice with subcutaneous xenografts demonstrated that this composite system significantly induced tumor vascular thrombosis and inhibited tumor growth, whereas these histological changes were not observed in normal organs.
Asunto(s)
Antineoplásicos Inmunológicos/administración & dosificación , Neoplasias Hepáticas/tratamiento farmacológico , Neuropilina-1/inmunología , Tromboplastina/administración & dosificación , Trombosis/inducido químicamente , Animales , Antineoplásicos Inmunológicos/química , Antineoplásicos Inmunológicos/farmacología , Factor X/metabolismo , Femenino , Células Hep G2 , Células Endoteliales de la Vena Umbilical Humana , Humanos , Neoplasias Hepáticas/irrigación sanguínea , Neoplasias Hepáticas/metabolismo , Ratones , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/farmacología , Estreptavidina/química , Tromboplastina/química , Tromboplastina/farmacología , Trombosis/metabolismo , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Essentials The coagulation initiator, tissue factor (TF), is on the herpes simplex virus 1 (HSV1) surface. HSV1 surface TF was examined in mice as an antiviral target since it enhances infection in vitro. HSV1 surface TF facilitated infection of all organs evaluated and anticoagulants were antiviral. Protease activated receptor 2 inhibited infection in vivo and its pre-activation was antiviral. SUMMARY: Background Tissue factor (TF) is the essential cell surface initiator of coagulation, and mediates cell signaling through protease-activated receptor (PAR) 2. Having a diverse cellular distribution, TF is involved in many biological pathways and pathologies. Our earlier work identified host cell-derived TF on the envelope covering several viruses, and showed its involvement in enhanced cell infection in vitro. Objective In the current study, we evaluated the in vivo effects of virus surface TF on infection and on the related modulator of infection PAR2. Methods With the use of herpes simplex virus type 1 (HSV1) as a model enveloped virus, purified HSV1 was generated with or without envelope TF through propagation in a TF-inducible cell line. Infection was studied after intravenous inoculation of BALB/c, C57BL/6J or C57BL/6J PAR2 knockout mice with 5 × 105 plaque-forming units of HSV1, mimicking viremia. Three days after inoculation, organs were processed, and virus was quantified with plaque-forming assays and quantitative real-time PCR. Results Infection of brain, lung, heart, spinal cord and liver by HSV1 required viral TF. Demonstrating promise as a therapeutic target, virus-specific anti-TF mAbs or small-molecule inhibitors of coagulation inhibited infection. PAR2 modulates HSV1 in vivo as demonstrated with PAR2 knockout mice and PAR2 agonist peptide. Conclusion TF is a constituent of many permissive host cell types. Therefore, the results presented here may explain why many viruses are correlated with hemostatic abnormalities, and indicate that TF is a novel pan-specific envelope antiviral target.
Asunto(s)
Herpes Simple/virología , Herpesvirus Humano 1/metabolismo , Tromboplastina/administración & dosificación , Proteínas del Envoltorio Viral/administración & dosificación , Animales , Anticoagulantes/farmacología , Antivirales/farmacología , Modelos Animales de Enfermedad , Femenino , Herpes Simple/sangre , Herpes Simple/tratamiento farmacológico , Herpes Simple/inmunología , Herpesvirus Humano 1/efectos de los fármacos , Herpesvirus Humano 1/inmunología , Interacciones Huésped-Patógeno , Inyecciones Intravenosas , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Noqueados , Receptor PAR-2/genética , Receptor PAR-2/metabolismo , Células TH1/inmunología , Células TH1/virología , Tromboplastina/metabolismo , Proteínas del Envoltorio Viral/metabolismoRESUMEN
The anticoagulant and antithrombotic properties of three structurally correlated sea urchin-derived 3-linked sulfated α-glycans and their low molecular-weight derivatives were screened comparatively through various in vitro and in vivo methods. These methods include activated partial thromboplastin time, the inhibitory activity of antithrombin over thrombin and factor Xa, venous antithrombosis, the inhibition of platelet aggregation, the activation of factor XII, and bleeding. While the 2-sulfated fucan from Strongylocentrotus franciscanus was observed to be poorly active in most assays, the 4-sulfated fucan from Lytechinus variegatus, the 2-sulfated galactan from Echinometra lucunter and their derivatives showed multiple effects. All marine compounds showed no capacity to activate factor XII and similar low bleeding tendencies regardless of the dose concentrations used to achieve the highest antithrombotic effect observed. The 2-sulfated galactan showed the best combination of results. Our work improves the background about the structure-function relationship of the marine sulfated glycans in anticoagulation and antithrombosis. Besides confirming the negative effect of the 2-sulfated fucose and the positive effect of the 2-sulfated galactose on anticoagulation in vitro, our results also demonstrate the importance of this set of structural requirements on antithrombosis in vivo, and further support the involvement of high-molecular weight and 4-sulfated fucose in both activities.
Asunto(s)
Anticoagulantes/farmacología , Factor XII/metabolismo , Fibrinolíticos/farmacología , Polisacáridos/farmacología , Erizos de Mar/química , Trombosis de la Vena/tratamiento farmacológico , Adulto , Animales , Anticoagulantes/química , Anticoagulantes/aislamiento & purificación , Anticoagulantes/uso terapéutico , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Factor Xa/metabolismo , Femenino , Fibrinolíticos/química , Fibrinolíticos/aislamiento & purificación , Fibrinolíticos/uso terapéutico , Voluntarios Sanos , Humanos , Masculino , Estructura Molecular , Peso Molecular , Tiempo de Tromboplastina Parcial , Polisacáridos/química , Polisacáridos/aislamiento & purificación , Polisacáridos/uso terapéutico , Conejos , Ratas , Ratas Wistar , Relación Estructura-Actividad , Sulfatos/química , Tromboplastina/administración & dosificación , Trombosis de la Vena/inducido químicamente , Adulto JovenRESUMEN
Targeting the human blood coagulation-inducing protein tissue factor (TF) to the tumor vasculature to induce infarction and disrupt the blood vessels has proven to be an effective approach for tumor therapy. In this study, we investigated the thrombogenic activity and anti-tumor potential of a novel fusion protein (tTF-CREKA) comprising the extracellular domain of human tissue factor (truncated TF, tTF) and a tumor targeting pentapeptide, Cys-Arg-Glu-Lys-Ala (CREKA). tTF is soluble and inactive in its free state, but when it is targeted to the plasma membrane of both tumor vessel endothelial cells and stromal cells by the CREKA peptide, its native coagulation-inducing activity is restored. Systemic administration of the tTF-CREKA fusion protein into tumor-bearing mice induced tumor-selective intravascular thrombosis and reduced tumor blood perfusion, consequently inhibiting tumor growth. The development of tTF-CREKA introduces a new method for treating a wide spectrum of solid tumors by selectively blocking tumor blood supply.
Asunto(s)
Neoplasias/tratamiento farmacológico , Neovascularización Patológica/tratamiento farmacológico , Tromboplastina/administración & dosificación , Tromboplastina/uso terapéutico , Animales , Línea Celular Tumoral , Clonación Molecular , Sistemas de Liberación de Medicamentos , Hemostáticos/administración & dosificación , Hemostáticos/uso terapéutico , Infarto , Ratones Endogámicos BALB C , Ratones Desnudos , Neoplasias/irrigación sanguínea , Proteínas Recombinantes , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
INTRODUCTION: Factor VIII (FVIII) or factor IX (FIX)-deficient haemophilic patients display deficits in platelet and fibrin deposition under flow detectable in microfluidics. Compared to fibrin generation, decreased platelet deposition in haemophilic blood flow is more easily rescued with recombinant factor VIIa (rFVIIa), whereas rFVIIa requires FXIIa participation to generate fibrin when tissue factor (TF) is absent. AIMS: Perfusion of haemophilic whole blood (WB) over collagen/TF surfaces was used to determine whether rFVIIa/TF was sufficient to bypass poor FIXa/FVIIIa function in blood from patients with haemophilia A and B. METHODS: Whole blood treated with high-dose corn trypsin inhibitor (40 µg mL-1 ) from seven healthy donors and 10 patients was perfused over fibrillar collagen presenting low or high TF (TFlow or TFhigh ) at wall shear rate of 100 s-1 . RESULTS: With WB from healthy controls, platelet deposition and fibrin accumulation increased as TF increased. Factor-deficient WB (1-3% of normal) displayed striking deficits in platelet deposition and fibrin formation at either TFlow or TFhigh . In contrast, mildly factor-deficient WB (14-32%) supported fibrin formation under flow on TFhigh /collagen. With either TFlow or TFhigh , exogenously added rFVIIa (20 nm) increased platelet deposition and fibrin accumulation in WB from factor-deficient patients (1-3% of normal) to levels commensurate with untreated healthy WB. CONCLUSION: The absence of FIXa/FVIIIa in patients with severe haemophilia results in deficits in fibrin formation that cannot be rescued by wall-derived TF ex vivo. The effects of rFVIIa on platelet adhesion and rFVIIa/TF can act together to reinforce thrombin generation, platelet deposition and fibrin formation under flow.
Asunto(s)
Colágeno/administración & dosificación , Factor VIIa/administración & dosificación , Fibrina/biosíntesis , Hemofilia A/sangre , Hemofilia A/tratamiento farmacológico , Hemofilia B/sangre , Hemofilia B/tratamiento farmacológico , Tromboplastina/administración & dosificación , Coagulación Sanguínea/efectos de los fármacos , Pruebas de Coagulación Sanguínea , Plaquetas/metabolismo , Colágeno/metabolismo , Hemofilia A/diagnóstico , Hemofilia B/diagnóstico , Humanos , Modelos Biológicos , Activación Plaquetaria/efectos de los fármacos , Adhesividad Plaquetaria/efectos de los fármacos , Unión Proteica , Proteínas Recombinantes/administración & dosificación , Transducción de Señal , Tromboplastina/metabolismoRESUMEN
BACKGROUND: The use of prothrombin complex concentrates in trauma- and surgery-induced coagulopathy is complicated by the possibility of thromboembolic events. To explore the effects of these agents on thrombin generation (TG), we investigated combinations of coagulation factors equivalent to 3- and 4-factor prothrombin complex concentrates with and without added antithrombin (AT), as well as recombinant factor VIIa (rFVIIa), in a dilutional model. These data were then used to develop a computational model to test whether such a model could predict the TG profiles of these agents used to treat dilutional coagulopathy. METHODS: We measured TG in plasma collected from 10 healthy volunteers using Calibrated Automated Thrombogram. TG measurements were performed in undiluted plasma, 3-fold saline-diluted plasma, and diluted plasma supplemented with the following factors: rFVIIa (group rFVIIa); factors (F)II, FIX, FX, and AT (group "combination of coagulation factors" [CCF]-AT); or FII, FVII, FIX, and FX (group CCF-FVII). We extended an existing computational model of TG to include additional reactions that impact the Calibrated Automated Thrombogram readout. We developed and applied a computational strategy to train the model using only a subset of the obtained TG data and used the remaining data for model validation. RESULTS: rFVIIa decreased lag time and the time to thrombin peak generation beyond their predilution levels (P < 0.001) but did not restore normal thrombin peak height (P < 0.001). CCF-FVII supplementation decreased lag time (P = 0.034) and thrombin peak time (P < 0.001) and increased both peak height (P < 0.001) and endogenous thrombin potential (P = 0.055) beyond their predilution levels. CCF-AT supplementation in diluted plasma resulted in an improvement in TG without causing the exaggerated effects of rFVIIa and CCF-FVII supplementation. The differences between the effects of CCF-AT and supplementation with rFVIIa and CCF-FVII were significant for lag time (P < 0.001 and P = 0.005, respectively), time to thrombin peak (P < 0.001 and P = 0.004, respectively), velocity index (P < 0.001 and P = 0.019, respectively), thrombin peak height (P < 0.001 for both comparisons), and endogenous thrombin potential (P = 0.034 and P = 0.019, respectively). The computational model generated subject-specific predictions and identified typical patterns of TG improvement. CONCLUSIONS: In this study of the effects of hemodilution, CCF-AT supplementation improved the dilution-impaired plasma TG potential in a more balanced way than either rFVIIa alone or CCF-FVII supplementation. Predictive computational modeling can guide plasma dilution/supplementation experiments.
Asunto(s)
Antitrombinas/administración & dosificación , Modelos Teóricos , Trombina/metabolismo , Tromboplastina/administración & dosificación , Pruebas de Coagulación Sanguínea/métodos , Factor VIIa/administración & dosificación , Humanos , Proteínas Recombinantes/administración & dosificación , Trombina/antagonistas & inhibidoresRESUMEN
PURPOSE: The aim of this study was to compare the efficacy, safety, and cost-effectiveness of 3-factor prothrombin complex concentrate (3F-PCC) vs 4-factor prothrombin complex concentrate PCC (4F-PCC) in trauma patients requiring reversal of oral anticoagulants. MATERIALS AND METHODS: All consecutive trauma patients with coagulopathy (international normalized ratio [INR] ≥1.5) secondary to oral anticoagulants who received either 3F-PCC or 4F-PCC from 2010 to 2014 at 2 trauma centers were reviewed. Efficacy was determined by assessing the first INR post-PCC administration, and successful reversal was defined as INR less than 1.5. Safety was assessed by reviewing thromboembolic events, and cost-effectiveness was calculated using total treatment costs (drug acquisition plus transfusion costs) per successful reversal. RESULTS: Forty-six patients received 3F-PCC, and 18 received 4F-PCC. Baseline INR was similar for 3F-PCC and 4F-PCC patients (3.1 ± 2.3 vs 3.4 ± 3.7, P = .520). The initial PCC dose was 29 ± 9 U/kg for 3F-PCC and 26 ± 6 U/kg for 4F-PCC (P = .102). The follow-up INR was 1.6 ± 0.6 for 3F-PCC and 1.3 ± 0.2 for 4F-PCC (P = .001). Successful reversal rates in patients were 83% for 4F-PCC and 50% for 3F-PCC (P = .022). Thromboembolic events were observed in 15% of patients with 3F-PCC vs 0% with 4F-PCC (P = .177). Cost-effectiveness favored 4F-PCC ($5382 vs $3797). CONCLUSIONS: Three-factor PCC and 4F-PCC were both safe in correcting INR, but 4F-PCC was more effective, leading to better cost-effectiveness. Replacing 3F-PCC with 4F-PCC for urgent coagulopathy reversal may benefit patients and institutions.
Asunto(s)
Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Calcio/uso terapéutico , Hemostáticos/uso terapéutico , Tromboplastina/uso terapéutico , Heridas y Lesiones , Anciano , Anticoagulantes/efectos adversos , Trastornos de la Coagulación Sanguínea/sangre , Calcio/administración & dosificación , Calcio/economía , Análisis Costo-Beneficio , Cuidados Críticos , Femenino , Hemostáticos/administración & dosificación , Hemostáticos/economía , Humanos , Relación Normalizada Internacional , Masculino , Estudios Retrospectivos , Seguridad , Tromboplastina/administración & dosificación , Tromboplastina/economía , Centros Traumatológicos , Warfarina/efectos adversosRESUMEN
OBJECTIVES: TT-173 is a new hemostatic agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans. METHODS: This is a phase I, randomized, placebo-controlled study to evaluate the efficacy, safety, systemic absorption, and immunogenicity of TT-173 in healthy volunteers undergoing tooth extraction. Subjects received TT-173 or placebo into the alveolar cavity, just after tooth extraction. Time to clot formation, bleeding time, and adverse events were recorded. RESULTS: Treatment with TT-173 reduced the bleeding time and the time to clot formation. No adverse events related with product administration were reported. In the same way, neither systemic absorption nor immunogenic reaction against the product was detected. Our findings pave the way to evaluate the usefulness of this new topical hemostatic agent in more complex oral surgeries and in those patients affected with coagulation disorders that may compromise the realization of dental procedures. CONCLUSION: The new hemostatic agent TT-173 has proven efficacious and safe in healthy subjects undergoing tooth extraction supporting its further evaluation in more complex surgeries. CLINICAL RELEVANCE: The development of this new topical hemostatic agent could contribute to bleeding control in oral and maxillofacial surgery.
Asunto(s)
Hemostáticos/farmacología , Hemorragia Bucal/prevención & control , Tromboplastina/farmacología , Extracción Dental , Administración Tópica , Adulto , Femenino , Hemostáticos/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Método Simple Ciego , Tromboplastina/administración & dosificación , Resultado del TratamientoRESUMEN
As espécies reativas ao oxigênio (EROS) são produzidas como mecanismo de defesa celular, participando dos processos de cicatrização celular. Entretanto, altos níveis de EROS podem causar danos como a peroxidação lipídica (PL). O presente estudo teve como objetivo, verificar os níveis de PL por meio da determinação das substâncias reativas ao ácido tiobarbitúrico (TBARS) no plasma de ratos com lesão tecidual induzida. Foram utilizados 32 ratos machos, Rattus norvegicus albinus da linhagem Wistar, os quais foram pesados e da média ± 10% do peso foram distribuídos em quatro grupos: A controle negativo; B - Vetaglós®; C hidrogel de poliamido de mandioca+ Vetaglós®; D Hidrogel de poliamido de mandioca. Após 21 dias, todos os animais foram anestesiados com isoflurano e foi feita a coleta de sangue por punção cardíaca, e os plasmas foram obtidos após centrifugação, na sequência por superdosagem do anestésico foi realizada a eutanásia. Os níveis de PL nos plasmas dos ratos foram determinados pelo método do TBARS. Não houve diferença significativa entre os grupos em relação à PL, indicando um equilíbrio entre as defesas antioxidantes celulares e os níveis de EROS produzidos durante o processo de cicatrização celular. Essa ausência nos diferentes grupos experimentais, em relação à PL, deixa claro a importância de se contemplar estudos de parâmetros de bioindicadores de estresse oxidativo em protocolos experimentais.
Reactive oxygen species (ROS) are produced as a cellular defense mechanism, participating in the processes of cellular healing. However, high levels of ROS can cause damages such as lipid peroxidation (LPO). This study aimed to verify the levels of LPO through the determination of reactive substances to thiobarbituric acid (TBARS) in rat plasma with induced tissue injury. A total of 32 Rattus norvegicus albinus Wistar were used, with a mean weight ± 10%. They were divided into four groups: A negative control; B - Vetaglós®; C - Polyamide cassava; D - Polyamide cassava + Vetaglós®. After 21 days, all animals were anesthetized with isoflurane and blood was collected by cardiac puncture. Plasma was obtained after centrifugation. Euthanasia was performed with administration of an overdose of inhalational anesthetic previously used. The LPO levels in rat plasma were determined using the TBARS method. There was no significant difference between the groups in relation to LPO, indicating a balance between antioxidant defenses and cellular levels of ROS produced during the cellular healing process. This absence in the different experimental groups in relation to LPO emphasizes the importance of further studies related to the bio-indicator parameters for oxidative stress in experimental protocols.
Las especies reactivas al oxígeno (EROS) se producen como mecanismo de defensa celular, que participan en los procesos de curación celulares. Sin embargo, los altos niveles de EROS pueden causar daños como la peroxidación lipídica (PL). Este estudio tuvo como objetivo verificar los niveles de peroxidación lipídica por sustancias reactivas al ácido tiobarbitúrico (TBARS) en el plasma de ratas con lesión tisular inducida. Se han utilizado 32 ratas machos, Rattus norvegicus albinus de linaje Wistar, que se pesaron y la media ± 10% en peso, y se dividieron en cuatro grupos: A control negativo; B - Vetaglós®; C hidrogel de poliamida de yuca + Vetaglós®; D Hidrogel de poliamida de yuca. Después de 21 días, todos los animales fueron anestesiados con isoflurano y se hizo la extracción de sangre por punción cardiaca, y se obtuvieron los plasmas después de la centrifugación, enseguida con sobredosis de anestésico se realizó la eutanasia. Los niveles de PL en los plasmas de las ratas se determinaron por el método de TBARS. No hubo diferencia significativa entre los grupos en relación a la peroxidación lipídica, lo que indica un equilibrio entre las defensas antioxidantes celulares y los niveles de EROS producidos durante el proceso de curación celular. Esa ausencia en los diferentes grupos experimentales, en relación a la PL, pone de manifiesto la importancia de contemplarse estudios de parámetros de bioindicadores de estrés oxidativo en los protocolos experimentales.
Asunto(s)
Animales , Ratas , Hidrogeles/análisis , Peroxidación de Lípido , Especies Reactivas de Oxígeno/análisis , Tromboplastina/administración & dosificaciónRESUMEN
Antecedentes: El monitoreo del tratamiento con anticoagulantes cumarínicos se realiza a través del INR (International Normalized Ratio) que es el parámetro estandarizado del Tiempo de Protrombina. Las recomendaciones de la OMS indican que la precisión en el cálculo del INR puede ser mejorada usando reactivo de tromboplastina con Indice de Sensibilidad Internacional (ISI) bajo, considerándose como ISI de referencia internacional el valor 1,0. Debido a incongruencias observadas en los INR de pacientes controlados en el Servicio de Salud Metropolitano Occidente, comparando valores de muestra venosa con resultados de INR capilar obtenidos en el mismo paciente el mismo día y hora (con reactivos Tromboplastina de distinto ISI), se efectuó un ensayo clínico cruzado entre los distintos métodos. Materiales y métodos: En 100 pacientes se comparó INR venoso con dos tromboplastinas de diferente ISI (1,3 y 1,0) vs aquel efectuado con muestra capilar (ISI 1,0). Resultados: Los resultados del estudio muestran que a partir de valores de INR 3,0 las determinaciones obtenidas usando Tromboplastina de cerebro de conejo ISI=1,3 subestiman el valor de INR para un mismo paciente y una misma muestra. Conclusiones: El uso de Tromboplastina recombinante humana ISI 1,0 permite evitar la subestimación del INR en pacientes con mayor riesgo tromboembóli-co (indicación de INR objetivo más alto). Por ello, este método se adoptó en el control del TACO en pacientes controlados en el Servicio de Salud Occidente.
Background: INR (International Normalized Ratio) is the standard Prothrombin Time parameter for monitoring anticoagulant treatment with coumarin derivatives Recommendations of WHO indicate that precision in the calculation of the INR can be improved using thromboplastins with a low Index of International Sensibility (ISI=1,0). Discrepancies in INR obtained using either this technique or conventional rabbit brain derived reagents in the same sample in patients attending the Servicio de Salud Metropolitano Occidente (West Metropolitan Health Service) were observed. Our objective was to evaluate these discrepancies in a systematic way. Materials and methods: A comparative study was conducted using two thromboplastins of different ISI (1.0 and 1.3) for the calculation of venous INR in comparison with capillary INR in 100 patients. Results: The study showed that INR values may differ significantly according to the method used. In particular, rabbit brain thromboplastin ISI = 1.3 underestimates the value of INR in the range of INR ≥3.0. Conclusions: The use of human recombinant thromboplastin ISI= 1.0. for determination of INR may significantly decrease the risk of hemorrhagic complications in patients requiring higher levels of anticoagulation.
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Coagulación Sanguínea/efectos de los fármacos , Tromboplastina/administración & dosificación , Tromboplastina/normas , Acenocumarol/administración & dosificación , Tiempo de Protrombina , Hemostáticos/administración & dosificación , Administración Oral , Relación Normalizada Internacional , AnticoagulantesRESUMEN
Autophagy has an important role in tumor biology of hepatocellular carcinoma (HCC). Recent studies demonstrated that tissue factor (TF) combined with coagulation factor VII (FVII) has a pathological role by activating a G-protein-coupled receptor called protease-activated receptor 2 (PAR2) for tumor growth. The present study aimed to investigate the interactions of autophagy and the coagulation cascade in HCC. Seventy HCC patients who underwent curative liver resection were recruited. Immunohistochemical staining and western blotting were performed to determine TF, FVII, PAR2 and light chain 3 (LC3A/B) expressions in tumors and their contiguous normal regions. We found that the levels of autophagic marker LC3A/B-II and coagulation proteins (TF, FVII and PAR2) were inversely correlated in human HCC tissues. Treatments with TF, FVII or PAR2 agonist downregulated LC3A/B-II with an increased level of mTOR in Hep3B cells; in contrast, knockdown of TF, FVII or PAR2 increased LC3A/B. Furthermore, mTOR silencing restored the impaired expression of LC3A/B-II in TF-, FVII- or PAR2-treated Hep3B cells and activated autophagy. Last, as an in vivo correlate, we administered TF, FVII or PAR2 agonist in a NOD/severe combined immunodeficiency xenograft model and showed decreased LC3A/B protein levels in HepG2 tumors with treatments. Overall, our present study demonstrated that TF, FVII and PAR2 regulated autophagy mainly via mTOR signaling. The interaction of coagulation and autophagic pathways may provide potential targets for further therapeutic application in HCC.
Asunto(s)
Autofagia , Coagulación Sanguínea , Carcinoma Hepatocelular/sangre , Carcinoma Hepatocelular/patología , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/patología , Animales , Antineoplásicos/farmacología , Autofagia/efectos de los fármacos , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/genética , Proliferación Celular , Factor VII/administración & dosificación , Factor VII/genética , Factor VII/metabolismo , Células Hep G2 , Humanos , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/genética , Ratones , Ratones Endogámicos NOD , Ratones SCID , Proteínas Asociadas a Microtúbulos/genética , Proteínas Asociadas a Microtúbulos/metabolismo , Oligopéptidos/farmacología , Interferencia de ARN , Receptor PAR-2/agonistas , Receptor PAR-2/genética , Receptor PAR-2/metabolismo , Transducción de Señal , Serina-Treonina Quinasas TOR/genética , Serina-Treonina Quinasas TOR/metabolismo , Tromboplastina/administración & dosificación , Tromboplastina/genética , Tromboplastina/metabolismo , Factores de Tiempo , Transfección , Carga Tumoral , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Radiosurgery for glioblastoma is limited to the development of resistance, allowing tumor cells to survive and initiate tumor recurrence. Based on our previous work that coadministration of tissue factor and lipopolysaccharide following radiosurgery selectively induced thrombosis in cerebral arteriovenous malformations, achieving thrombosis of 69% of the capillaries and 39% of medium sized vessels, we hypothesized that a rapid and selective shutdown of the capillaries in glioblastoma vasculature would decrease the delivery of oxygen and nutrients, reducing tumor growth, preventing intracranial hypertension, and improving life expectancy. Glioblastoma was formed by implantation of GL261 cells into C57Bl/6 mouse brain. Mice were intravenously injected tissue factor, lipopolysaccharide, a combination of both, or placebo 24 hours after radiosurgery. Control mice received both agents after sham irradiation. Coadministration of tissue factor and lipopolysaccharide led to the formation of thrombi in up to 87 ± 8% of the capillaries and 46 ± 4% of medium sized vessels within glioblastoma. The survival rate of mice in this group was 80% versus no survivor in placebo controls 30 days after irradiation. Animal body weight increased with time in this group (r = 0.88, P = 0.0001). Thus, radiosurgery enhanced treatment with tissue factor, and lipopolysaccharide selectively induces thrombosis in glioblastoma vasculature, improving life expectancy.
Asunto(s)
Glioblastoma/cirugía , Neoplasias Experimentales/cirugía , Radiocirugia , Trombosis/cirugía , Animales , Terapia Combinada , Modelos Animales de Enfermedad , Glioblastoma/inducido químicamente , Glioblastoma/complicaciones , Glioblastoma/patología , Humanos , Lipopolisacáridos/toxicidad , Ratones , Recurrencia Local de Neoplasia , Neoplasias Experimentales/inducido químicamente , Neoplasias Experimentales/patología , Tromboplastina/administración & dosificación , Trombosis/inducido químicamente , Trombosis/complicaciones , Trombosis/patologíaRESUMEN
Trauma-induced tissue factor (TF) release into the systemic circulation is considered to play an important role in the development of disseminated intravascular coagulation (DIC) immediately after severe trauma. However, the relationship between TF and hyperfibrinolysis, especially fibrinogenolysis, has been unclear. A total of 18 rats were divided into three groups: (a) the control group was infused with normal saline; (b) the low-dose group was infused with 4 U/kg TF; and (c) the high-dose group was infused with 16 U/kg TF. Arterial blood was drawn immediately and 2 and 4 h after the start of TF infusion. At each sampling point, arterial blood gases, platelet counts, and coagulation variables were measured. The fibrinogen degradation products were evaluated by a Western blot analysis. Hypotension, hypoxemia, and lactic acidosis were not observed in any of the three groups. In proportion to the doses of TF, the platelet counts, coagulation, and fibrinolysis variables deteriorated in line with DIC. The α2-plasmin inhibitor levels significantly decreased in the high-dose group compared with the other groups. The amounts of fibrinogen degradation products increased in proportion to the doses of TF. The plasmin-α2-plasmin inhibitor complex level in the high-dose group increased more than that of the other groups. In conclusion, TF can induce DIC associated with fibrinolysis and fibrinogenolysis without tissue hypoperfusion. The decrease in the α2-plasmin inhibitor level and the significant increase in the plasmin level may be the two main factors underlying the pathogenesis of hyperfibrin(ogen)olysis after TF administration.
Asunto(s)
Coagulación Intravascular Diseminada/sangre , Fibrinólisis/efectos de los fármacos , Tromboplastina/farmacología , Animales , Coagulación Sanguínea/efectos de los fármacos , Presión Sanguínea/efectos de los fármacos , Coagulación Intravascular Diseminada/inducido químicamente , Relación Dosis-Respuesta a Droga , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Fibrinógeno/metabolismo , Hemoglobinas/metabolismo , Masculino , Oxígeno/sangre , Presión Parcial , Recuento de Plaquetas , Ratas , Ratas Wistar , Tromboplastina/administración & dosificación , alfa 2-Antiplasmina/metabolismoRESUMEN
INTRODUCTION: The thrombogenic potential of tissue factor (TF) associated to platelets is controversial. We have investigated the in vitro contribution of platelet-associated TF to thrombus formation. MATERIALS AND METHODS: Platelets suspensions were exposed to human TF-rich microvesicles (TF-MV) from placental or recombinant origin. Platelet-associated TF was quantified through coagulometric assays. Adhesive and cohesive properties of platelets containing TF were assessed in perfusion models using two thrombogenic surfaces: 1) type-I collagen, or 2) damaged vascular segments. Perfusion studies were performed with heparinized blood enriched with a 30% of washed platelets exposed to TF-MV vs. washed control platelets. Thrombin generation and thromboelastometric properties of clots were also assessed using a fluorometric assay and ROTEM analysis, respectively. Inhibitory strategies with an antibody to TF were performed in some cases. RESULTS: The addition of 30% of platelets containing TF to blood perfusates resulted in a statistically significant increase in the platelet coverage (%CS) vs. non-exposed platelets on collagen surfaces (%CS: 19.7 ± 0.6 and 23.9 ± 0.7 respectively, vs.14.5 ± 1.4; p<0.01) and on the vascular subendothelium (%CS: 54.0 ± 1.5 and 47.2 ± 6.8 respectively vs. 38.0 ± 3.5, p<0.05), with a statistically significant increase in the size of large platelet aggregates (p<0.05) vs. control platelets. These effects on collagen surfaces were almost totally prevented by an antibody to TF. Platelet-associated TF significantly accelerated thrombin generation and clot formation (p<0.05), effects that were partially prevented by a neutralizing anti-TF. CONCLUSIONS: Platelet-associated TF potentiated adhesive and aggregating properties in in vitro studies with flowing blood and accelerated thrombin generation and clot formation time under steady conditions.
Asunto(s)
Plaquetas/efectos de los fármacos , Trombina/biosíntesis , Tromboplastina/administración & dosificación , Animales , Plaquetas/citología , Femenino , Humanos , Adhesividad Plaquetaria/efectos de los fármacos , Conejos , Factores de RiesgoRESUMEN
tTF-NGR consists of the extracellular domain of the (truncated) tissue factor (tTF), a central molecule for coagulation in vivo, and the peptide GNGRAHA (NGR), a ligand of the surface protein aminopeptidase N (CD13). After deamidation of the NGR-peptide moiety, the fusion protein is also a ligand for integrin αvß3 (CD51/CD61). Both surface proteins are upregulated on endothelial cells of tumor vessels. tTF-NGR showed binding to specific binding sites on endothelial cells in vitro as shown by flow cytometry. Subcutaneous injection of tTF-NGR into athymic mice bearing human HT1080 fibrosarcoma tumors induced tumor growth retardation and delay. Contrast enhanced ultrasound detected a decrease in tumor blood flow in vivo after application of tTF-NGR. Histological analysis of the tumors revealed vascular disruption due to blood pooling and thrombotic occlusion of tumor vessels. Furthermore, a lack of resistance was shown by re-exposure of tumor-bearing mice to tTF-NGR after regrowth following a first cycle of treatment. However, after subcutaneous (s.c.) push injection with therapeutic doses (1-5 mg/kg bw) side effects have been observed, such as skin bleeding and reduced performance. Since lethality started within the therapeutic dose range (LD10 approximately 2 mg/kg bw) no safe therapeutic window could be found. Limiting toxicity was represented by thrombo-embolic events in major organ systems as demonstrated by histology. Thus, subcutaneous injection of tTF-NGR represents an active, but toxic application procedure and compares unfavourably to intravenous infusion.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Infarto/inducido químicamente , Neoplasias/irrigación sanguínea , Neoplasias/tratamiento farmacológico , Oligopéptidos/administración & dosificación , Tromboplastina/administración & dosificación , Inhibidores de la Angiogénesis/administración & dosificación , Inhibidores de la Angiogénesis/efectos adversos , Animales , Vasos Sanguíneos/efectos de los fármacos , Vasos Sanguíneos/patología , Línea Celular Tumoral , Células Cultivadas , Humanos , Inyecciones Subcutáneas , Ratones , Ratones Desnudos , Neovascularización Patológica/tratamiento farmacológico , Neovascularización Patológica/patología , Oligopéptidos/efectos adversos , Oligopéptidos/química , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/efectos adversos , Proteínas Recombinantes de Fusión/química , Tromboplastina/efectos adversos , Tromboplastina/química , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
We report the effects of a chemically oversulfated chondroitin sulfate and a naturally fucosylated chondroitin sulfate on the coagulation system. The former has been recently identified as a contaminant of heparin preparations and the latter has been proposed as an alternative anticoagulant. The mechanism of action of these polymers on coagulation is complex and target different components of the coagulation system. They have serpin-independent anticoagulant activity, which preponderates in plasma. They also have serpin-dependent anticoagulant activity but differ significantly in the target coagulation protease and preferential serpin. Their anticoagulant effects differ even more markedly when tested as inhibitors of coagulation proteases using plasma as a source of serpins. It is possible that the difference is due to the high availability of fucosylated chondroitin sulfate whereas oversulfated chondroitin sulfate has strong unspecific binding to plasma protein and low availability for the binding to serpins. When tested using a venous thrombosis experimental model, oversulfated chondroitin sulfate is less potent as an antithrombotic agent than fucosylated chondroitin sulfate. These highly sulfated chondroitin sulfates activate factor XII in in vitro assays, based on kallikrein release. However, only fucosylated chondroitin sulfate induces hypotension when intravenously injected into rats. In conclusion, the complexity of the regulatory mechanisms involved in the action of highly sulfated polysaccharides in coagulation requires their analysis by a combination of in vitro and in vivo assays. Our results are relevant due to the urgent need for new anticoagulant drugs or alternative sources of heparin.
Asunto(s)
Sulfatos de Condroitina/farmacología , Trombosis de la Vena/tratamiento farmacológico , Animales , Anticoagulantes/farmacología , Anticoagulantes/uso terapéutico , Coagulación Sanguínea/efectos de los fármacos , Presión Sanguínea/efectos de los fármacos , Bovinos , Sulfatos de Condroitina/química , Sulfatos de Condroitina/aislamiento & purificación , Sulfatos de Condroitina/uso terapéutico , Cromatografía de Afinidad , Perros , Factor XII/metabolismo , Heparina/farmacología , Heparina/uso terapéutico , Caballos , Humanos , Modelos Animales , Tiempo de Tromboplastina Parcial , Ratas , Tromboplastina/administración & dosificación , Trombosis de la Vena/sangre , Trombosis de la Vena/inducido químicamenteRESUMEN
Increasing reports of bleeding and peri- or post-operative blood dyscrasias in Brazil were possibly associated with the use of heparin from bovine instead of porcine intestine. These two pharmaceutical grade heparins were analysed for potential differences. NMR analyses confirmed that porcine heparin is composed of mainly trisulfated disaccharides -->4-alpha-IdoA2S-1-->4-alpha-GlcNS6S-1-->. Heparin from bovine intestine is also composed of highly 2-sulfated alpha-iduronic acid residues, but the sulfation of the alpha-glucosamine units vary significantly: approximately 50% are 6- and N -disulfated, as in porcine heparin, while approximately 36% are 6-desulfated and approximately 14% N -acetylated. These heparins differ significantly in their effects on coagulation, thrombosis and bleeding. Bovine heparin acts mostly through factor Xa. Compared to porcine heparin on a weight basis, bovine heparin exhibited approximately half of the anticoagulant and antithrombotic effects, but similar effect on bleeding. These two heparins also differ in their protamine neutralisation curves. The doses of heparin from bovine intestine required for effective antithrombotic protection and the production of adverse bleeding effects are closer than those for porcine heparin. This observation may explain the increasing bleeding observed among Brazilian patients. Our results suggest that these two types of heparin are not equivalent drugs.
Asunto(s)
Disacáridos/química , Heparina/química , Heparina/farmacología , Trombosis de la Vena/tratamiento farmacológico , Animales , Coagulación Sanguínea/efectos de los fármacos , Bovinos , Factor Xa/metabolismo , Hemorragia/etiología , Heparina/aislamiento & purificación , Heparina/metabolismo , Heparina/uso terapéutico , Mucosa Intestinal/metabolismo , Resonancia Magnética Nuclear Biomolecular , Protaminas/metabolismo , Ratas , Ratas Wistar , Porcinos , Tromboplastina/administración & dosificación , Trombosis de la Vena/sangre , Trombosis de la Vena/inducido químicamenteRESUMEN
Validation of animal models of disseminated intravascular coagulation (DIC) to human DIC is crucial in order to translate findings in research models to treatment modalities for DIC in humans. ISTH classifications of overt and non-overt human DIC have proven to have a high diagnostic accuracy, but the scoring systems have rarely been applied to animal models of DIC. In this study, we use rabbit brain thromboplastin (thromboplastin) to induce DIC in a rabbit model and test the applicability of the ISTH criteria for standardized diagnosis of DIC. Cardiovascular and haematological parameters from rabbits, either saline-injected or administered 0.625, 1.25, 2.5 or 5 mg thromboplastin/kg as a single bolus, were collected at four timepoints over a 90 minute period. All groups of rabbits were scored at each time point according to the ISTH diagnostic criteria for non-overt DIC. Injection of 5 mg thromboplastin/kg was lethal. For the remaining groups, a dose dependent decrease in blood pressure, platelet count and fibrinogen level together with a dose dependent increase in prothrombin time, activated partial thromboplastin time, level of thrombin-antithrombin complexes, fibrin degradation products and number of thrombi in lung vasculature was seen. The administration of a bolus of 1.25 - 2.5 mg thromboplastin/kg to rabbits induced a reproducible dose dependent model of non-overt DIC according to the ISTH diagnostic criteria. We conclude that the non-overt ISTH score can be applied to evaluate severity and progression of DIC in a standardized manner in this thromboplastin induced rabbit model.
Asunto(s)
Modelos Animales de Enfermedad , Coagulación Intravascular Diseminada/clasificación , Tromboplastina/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Coagulación Intravascular Diseminada/inducido químicamente , Coagulación Intravascular Diseminada/diagnóstico , Relación Dosis-Respuesta a Droga , Femenino , Fibrinógeno/efectos de los fármacos , Recuento de Plaquetas , Tiempo de Protrombina , Conejos , Tromboplastina/administración & dosificación , Factores de TiempoRESUMEN
BACKGROUND: Tissue factor (TF)-bearing microparticles (MP) from different origins are thought to be involved in the pathogenesis of cancer-associated thrombosis. However, the role of circulating tumor cell-derived TF is not well understood. METHODS: TF antigen and activity were measured in MP generated in vitro from human TF-expressing cancer cells by ELISA and clotting or thrombin generation assays, respectively. TF antigen and activity were also measured in vivo in cell-free plasmas from mice previously injected with in vitro-generated MP or in cell-free plasmas from nude mice bearing orthotopically injected human cancer cells. RESULTS: Tumor cell-derived MP (TMP) exhibited strong TF-dependent procoagulant activity (PCA) in vitro and in vivo. Injection of TMP into mice was associated with acute thrombocytopenia and signs of shock, which were prevented by prior heparinization. Human TF antigen and activity could be detected in mouse cell-free plasmas up to 30 min after TMP injections. Human TF was detected in the spleen of injected mice and its clearance from circulation was delayed in splenectomized mice, suggesting the involvement of the spleen in the rapid clearance of circulating MP in vivo. Detectable levels of TF-dependent PCA and thrombin-antithrombin complex were found in cell-free plasmas from mice growing pancreatic human tumors, suggesting that circulating tumor-derived TF causes coagulation activation in vivo. CONCLUSIONS: MP derived from certain cancer cells exhibit TF-dependent PCA both in vitro and in vivo. These results provide new information about the specific contribution of tumor-derived MP to the hypercoagulable state observed in cancer.